TH1601000068A - N,6-bis(aryl compound) or heteroaryl)-1,3,5-triazine-2,4-diamine as an inhibitor of IDH2 mutations for cancer treatment - Google Patents

N,6-bis(aryl compound) or heteroaryl)-1,3,5-triazine-2,4-diamine as an inhibitor of IDH2 mutations for cancer treatment

Info

Publication number
TH1601000068A
TH1601000068A TH1601000068A TH1601000068A TH1601000068A TH 1601000068 A TH1601000068 A TH 1601000068A TH 1601000068 A TH1601000068 A TH 1601000068A TH 1601000068 A TH1601000068 A TH 1601000068A TH 1601000068 A TH1601000068 A TH 1601000068A
Authority
TH
Thailand
Prior art keywords
triazine
heteroaryl
diamine
inhibitor
bis
Prior art date
Application number
TH1601000068A
Other languages
Thai (th)
Other versions
TH171543A (en
Inventor
เจเรมี่อูทลี่ย์ ทราวินส์
Original Assignee
อักเกียส ฟาร์มาซูติคอลอิงค์
Filing date
Publication date
Application filed by อักเกียส ฟาร์มาซูติคอลอิงค์ filed Critical อักเกียส ฟาร์มาซูติคอลอิงค์
Publication of TH1601000068A publication Critical patent/TH1601000068A/en
Publication of TH171543A publication Critical patent/TH171543A/en

Links

TH1601000068A 2014-07-10 Compound N, 6-bis (aryl Or heteroeryl) -1,3,5-triazine-2,4-diamine As an IDH2 mutation inhibitor for cancer treatment TH171543A (en)

Publications (2)

Publication Number Publication Date
TH1601000068A true TH1601000068A (en) 2017-12-21
TH171543A TH171543A (en) 2017-12-21

Family

ID=

Similar Documents

Publication Publication Date Title
ZA201600210B (en) N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
IL291000A (en) Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
HK1247922A1 (en) Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer
DK3445767T3 (en) MACROCYCLIC MCL1 INHIBITORS FOR TREATMENT OF CANCER
DK3442947T3 (en) AMINE SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS
EA201692203A1 (en) TANK-BINDING KINAZ INHIBITING COMPOUNDS
DK3331915T3 (en) IMMUNE CHECKPOINT INHIBITORS FOR USE FOR THE TREATMENT OF BLOOD-CARRIED CANCER
DK3436444T3 (en) HETEROCYCLIC COMPOUND
ZA201700737B (en) Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
EA201692079A1 (en) INHIBITORS OF LYSINE-SPECIFIC DEMETILASE-1
DK3468965T3 (en) 1-TETRAHYDROPYRANYL CARBONYL-2,3-DIHYDRO-1H-INDOL COMPOUNDS FOR CANCER TREATMENT
DK3521282T3 (en) QUINAZOLINE DERIVATIVES USED FOR THE TREATMENT OF HIV
DK3148529T3 (en) COMPOUNDS FOR THE TREATMENT OF BRAIN CANCER
DK3374359T3 (en) DIHYDROIMIDAZOPYRAZINO DERIVATIVES USED FOR CANCER TREATMENT
EA201591509A1 (en) CDC7 INHIBITORS
MX2017003930A (en) Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds.
MA40774A (en) DIARYLEUREA DERIVATIVES AS KINASE P38 INHIBITORS
DK3458052T3 (en) Combination treatment of cancer
CY1123592T1 (en) AURORA A KINASE INHIBITOR
DK3353177T3 (en) TRICYCLIC HETEROCYCLES FOR CANCER TREATMENT
DK3373931T3 (en) Heterocyclic compounds for the treatment of disease
EA201791099A1 (en) QUINOLIN CARBOXAMIDE FOR USE IN THE TREATMENT OF LEUKEMIA
DK3500572T3 (en) CYTISIS DERIVATIVES FOR THE TREATMENT OF ADDICTION
KR20180084983A (en) Uses of Pyrimido-Pyrimidazinone for the Treatment of Cancer
TH1601000068A (en) N,6-bis(aryl compound) or heteroaryl)-1,3,5-triazine-2,4-diamine as an inhibitor of IDH2 mutations for cancer treatment